Live Breaking News & Updates on Approved Oral Aprepitant

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
News provided by
Share this article
Share this article
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2020 and highlighted recent corporate updates.
Recent Corporate Updates
Pain Management Franchise
New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration (FDA), continues under review. The FDA set a Prescription Drug User Fe ....

United Kingdom , David Szekeres , Heron Biochronomer , Prnewswire Heron Therapeutics Inc , European Commission , Drug Administration , European Commission Authorization , Exchange Commission , European Union , Health Canada , Heron Therapeutics Inc , Drug Application Resubmission , New Drug Application , Prescription Drug User Fee Act , Commission Authorization , Postoperative Pain , Greater Pain Reduction Compared , Current Standard Of Care , Bunionectomy Study , Product Sales , Net Product Sales , Product Sales Guidance , Approved Oral Aprepitant , Investigational New Drug , Barry Quart , Chief Executive Officer ,